KEAP1 and diabetes mellitus: Oral administration of RESV protected streptozotocin-nicotinamide-induced diabetic rats by attenuating hyperglycaemia-mediated oxidative stress and inflammatory cytokines via NRF2-Keap1 signalling [187].